On the stock market since 2018, it operates in the world of health and science. It has 4,900 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
The gap is $243.1M. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 78% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 32 buys and 16 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $27.20 — 283% above today’s price.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, GTBIF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GTBIF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.